Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?

Blood

Volumn 122, Issue 13, 2013, Pages 2286-2288

  Santini, Valeria ^a   Schemenau, Jennifer ^b   Levis, Alessandro ^c   Balleari, Enrico ^d   Sapena, Rosa ^e   Adès, Lionel ^f   Guerci, Agnès ^g   Beyne Rauzy, Odile ^h   Gourin, Marie Pierre ⁱ   Cheze, Stephane ^j   Stamatoullas, Aspasia ^k   Sanna, Alessandro ^a   Gioia, Daniela ^l   Cametti, Gianni ^m   Ferrero, Dario ⁿ   Raffoux, Emmanuel ^o   Rose, Christian ^p   Poloni, Antonella ^q   Prebet, Thomas ^r   Legros, Laurence ^s   Natarajan Amé, Shanti ^t   Fenaux, Pierre ^u   Germing, Ulrich ^b   Dreyfus, François ^v   Park, Sophie ^w   more..

^a Fundazion Italiana delle sindromi mielodisplastiche   (Italy)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c ASO Santi Antonio e Biagio   (Germany)

^d UNIVERSITY OF GENOA   (Italy)

^e Groupe Francophone des Myelodysplasies GFM   (France)

^f AVICENNE HOSPITAL   (France)

^g UNIVERSITY HOSPITAL OF NANCY   (France)

^h CHU PURPAN   (France)

ⁱ Groupe Francophone des Myélodysplasies   (France)

^j Groupe Francophone des Myélodysplasies GFM   (France)

^k Groupe Francophone des Myélodysplasies   (France)

^l Fundazion Italiana delle sindromi mielodisplastiche   (Italy)

^m Fundazion Italiana delle sindromi mielodisplastiche   (Italy)

ⁿ Fundazion Italiana delle sindromi mielodisplastiche   (Italy)

^o SAINT LOUIS HOSPITAL   (France)

^p UNIVERSITÉ CATHOLIQUE DE LILLE   (France)

^q UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^r Groupe Francophone des Myélodysplasies   (France)

^s Groupe Francophone des Myélodysplasies   (France)

^t HÔPITAL CIVIL   (France)

^u UNIVERSITÉ PARIS 13   (France)

^v ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^w GRENOBLE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL STIMULANT AGENT; ERYTHROPOIETIN; FERRITIN; ANTIANEMIC AGENT;

BLAST CELL; CYTOGENETICS; CYTOPENIA; ERYTHROCYTE TRANSFUSION; FERRITIN BLOOD LEVEL; HUMAN; INTERMEDIATE RISK PATIENT; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LETTER; LOW RISK PATIENT; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; FEMALE; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX;

FEMALE; HEMATINICS; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84887380862     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-07-512442     Document Type: Letter

References (5)

1. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6): 2079-2088.
2. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465.
3. Schanz J, Tüchler H, Solé F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30(8):820-829.
4. Hellström-Lindberg E, Gulbrandsen N, Lindberg G, et al; Scandinavian MDS Group. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin 1 granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120(6):1037-1046.
5. Kelaidi C, Park S, Sapena R, et al. Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents. Leukemia. 2013;27(6):1283-1290.